Drug Trial Radar · NCT03777254
Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Apr 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jan 7, 2019
Primary completion
Aug 20, 2019
Study completion Aug 20, 2019
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human study is to evaluate the safety, tolerability and pharmacokinetics of single intravitreous injections,single ascending doses, of RC28-E(a chimeric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in subjects with wet age-related macular degeneration (wAMD).
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
RC28-EBiological
RC28-E intravitreous injection 50ul
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular and systemic adverse events and serious adverse events which are related to RC28-ETime frame: 42 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital .Cmu
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.